New · CUSIP 08205P209 · who reports it, how much, and how much it matters to them
14 of the 720 hedge fund managers we track reported shares of Benitec Biopharma Inc. (Nasdaq: BNTC) on Form 13F for 30 June 2026. Between them they reported USD 243m. The largest position belongs to Suvretta Capital Management, at USD 155m. The manager with the most riding on it is Lion Point Capital, where it is 4.0% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management4 funds on PPLI.com | USD 155m | 2.8% |
| 2 | Adage Capital Management1 fund on PPLI.com | USD 28m | 0.0% |
| 3 | Ra Capital Management1 fund on PPLI.com | USD 25m | 0.2% |
| 4 | Millennium Management6 funds on PPLI.com | USD 12m | 0.0% |
| 5 | Balyasny Asset Management25 funds on PPLI.com | USD 8.7m | 0.0% |
| 6 | Myda Advisors4 funds on PPLI.com | USD 3.3m | 0.5% |
| 7 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 3.1m | 0.0% |
| 8 | Awm Investment Company6 funds on PPLI.com | USD 2.5m | 0.2% |
| 9 | Burkehill Global Management5 funds on PPLI.com | USD 2m | 0.1% |
| 10 | Citadel Advisors32 funds on PPLI.com | USD 1.1m | 0.0% |
| 11 | Lion Point Capital1 fund on PPLI.com | USD 830,000 | 4.0% |
| 12 | Atom Investors1 fund on PPLI.com | USD 650,000 | 0.1% |
| 13 | Entrypoint Capital1 fund on PPLI.com | USD 201,000 | 0.0% |
| 14 | Persistent Asset Partners10 funds on PPLI.com | USD 167,000 | 0.1% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Lion Point Capital | USD 830,000 | 4.0% |
| 2 | Suvretta Capital Management | USD 155m | 2.8% |
| 3 | Myda Advisors | USD 3.3m | 0.5% |
| 4 | Awm Investment Company | USD 2.5m | 0.2% |
| 5 | Ra Capital Management | USD 25m | 0.2% |
| 6 | Burkehill Global Management | USD 2m | 0.1% |
| 7 | Atom Investors | USD 650,000 | 0.1% |
| 8 | Persistent Asset Partners | USD 167,000 | 0.1% |
| 9 | Entrypoint Capital | USD 201,000 | 0.0% |
| 10 | Adage Capital Management | USD 28m | 0.0% |
Benitec Biopharma Inc. trades under the symbol BNTC on the Nasdaq. Its CUSIP, the code used on Form 13F, is 08205P209.
14 of the 720 hedge fund managers PPLI.com tracks reported Benitec Biopharma Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 155m), Adage Capital Management (USD 28m), Ra Capital Management (USD 25m), Millennium Management (USD 12m) and Balyasny Asset Management (USD 8.7m).
14 managers in our coverage reported it, and between them they run 127 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Lion Point Capital, where the position was 4.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Benitec Biopharma Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.